Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 316 to 330 of 627 results for prescribing

  1. Quality improvement resource for adult social care

    Implementing NICE guidance NICE guidance implementation toolkits Medicines and prescribing Measuring the use of NICE guidance Into...

  2. Individual circumstances and the risk of dependence: Do individual circumstances such as social distress, low income or limited access to alternative sources of support lead to an increased risk of problems associated with dependence on prescribed medicines?

    recommendation for research, see the rationale section on making decisions about prescribing and taking a dependence-forming medicine or...

    Research recommendation
    Published
    11 May 2022

  3. System-level factors and the risk of dependence: Do system-level factors, such as training received by prescribers alter the risk of developing problems associated with dependence on prescribed medicines?

    recommendation for research, see the rationale section on making decisions about prescribing and taking a dependence-forming medicine or...

    Research recommendation
    Published
    11 May 2022

  4. Older people: independence and mental wellbeing (NG32)

    This guideline covers interventions to maintain and improve the mental wellbeing and independence of people aged 65 or older and how to identify those most at risk of a decline.

    NICE guideline
    Published
    17 December 2015
    View recommendations

    Sections for NG32

  5. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    What are the most clinically effective interventions (including social prescribing and structured community support) for managing...

    Research recommendation
    Published
    12 November 2021

  6. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).

    Technology appraisal guidance
    Published
    24 September 2008
    View recommendations

    Sections for TA158

  7. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188

  8. Headaches in over 12s (QS42)

    This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 August 2013
    View quality statements

    Sections for QS42

  9. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    28 January 2016
    View quality statements

    Sections for QS112

  10. Contraceptive services for under 25s (PH51)

    This guideline covers contraceptive services for under-25s. It aims to ensure all under-25s are given advice and information on all types of contraception. This includes additional tailored support to meet the particular needs and choices of those who are socially disadvantaged or who may find it difficult to use these services.

    Public health guideline
    Published
    26 March 2014
    View recommendations

    Sections for PH51

  11. Fever in under 5s: assessment and initial management (NG143)

    This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.

    NICE guideline
    Last updated
    26 November 2021
    View recommendations

    Sections for NG143

  12. Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)

    Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.

    Technology appraisal guidance
    Published
    26 November 2014
    View recommendations

    Sections for TA323

  13. Cardiovascular disease: risk assessment and reduction, including lipid modification (NG238)

    This guideline covers identifying and assessing risk of cardiovascular disease (CVD) in adults without established CVD. It covers lifestyle changes and lipid-lowering treatment (including statins) for primary and secondary prevention of CVD, and includes guidance for people who also have diabetes or chronic kidney disease.

    NICE guideline
    Published
    14 December 2023
    View recommendations

    Sections for NG238

  14. Faecal microbiota transplant for recurrent Clostridioides difficile infection (HTG638)

    Evidence-based recommendations on faecal microbiota transplant for recurrent Clostridioides difficile infection.

    HealthTech guidance
    Published
    31 August 2022
    View recommendations

    Sections for HTG638

  15. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice